ENGLEWOOD, Colo., March 30, 2020 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced that it
has hired Rachelle (Chelle) Van
Burkleo as its Vice President of Sales.
Chelle brings more than 20 years of experience and an
exceptional level of expertise in med-tech device sales.
Previously, Chelle was Vice President of Sales and Marketing at
WiscMed where she led strategic marketing initiatives and business
sales plan development.
Prior to WiscMed, Chelle was a senior sales and business
development leader with Welch Allyn (Hillrom), a global medical
device manufacturer. She started her career at Welch Allyn in 1995,
working with physicians to advance frontline care. Throughout her
career, she has taken on numerous roles of progressive
responsibility ultimately helping healthcare systems improve
outcomes, lower cost of care and improve both the clinician and
patient experience.
Chelle holds a Texas Executive
Education certificate in general management and a bachelor's degree
in business from the Red McCombs School of Business at the
University of Texas – Austin.
Thomas Sandgaard, CEO, said: "We
are excited to have Chelle on board to lead our growing sales
organization covering the market for prescription-strength
electrotherapy for pain management. We continue to grow our sales
force across the country and expect to have 400 sales reps covering
the US before the end of the year."
About Zynex, Inc.
Zynex, founded in
1996, markets and sells its own design of electrotherapy medical
devices used for pain management and rehabilitation; and the
company's proprietary NeuroMove device designed to help recovery of
stroke and spinal cord injury patients. Zynex also has a blood
volume monitor for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains
forward-looking statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical
fact.
In some cases, you can identify forward-looking statements by
terminology, such as
"expects," "anticipates," "intends," "estimates," "plans," "believes," "seeks," "may," "should," "could," "will," "future," "projects," "strategy," or
the negative of such terms or other similar expressions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause actual results to materially differ from forward-looking
statements include, but are not limited to, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2019.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-appoints-rachelle-van-burkleo-vice-president-of-sales-301031286.html
SOURCE Zynex